Clinical trial
Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or…
NCT00005871 · Astex Pharmaceuticals, Inc., Industry · Unknown status
Key facts
| NCT number | NCT00005871 |
|---|---|
| Title | Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer |
| Official title | Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) Versus 5-Fluorouracil (5-FU) in Pancreatic Cancer Patients That Have Progressive Disease Following Gemcitabine HCl Treatment |
| Lead sponsor | Astex Pharmaceuticals, Inc., Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | fluorouracil, rubitecan |
| Start date | Nov 1, 1998 |
| First posted | May 3, 2004 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: